Nebulizer

Alternative Media: Pharma Online: Not Just Black and White (Pharmaceutical Executive) - 203 weeks ago

Industry has room to grow in online multicultural marketing. Multicultural marketing represents a huge opportunity for pharma companies to go after a largely untapped audience.

Be careful what you eat: area school districts taking peanut allergies seriously (Redwood Falls Gazette) - 203 weeks ago

Jacob Welu doesn't like peanuts. For the MILROY Charter School fourth grader, that is a good thing.

School nurses work to care for students with chronic conditions (The Star Press) - 203 weeks ago

MUNCIE -- School nurses don't just take care of scraped knees, broken bones and the occasional child with an upset stomach. A growing number of students with diabetes, severe asthma or allergies and seizure disorders, feeding tubes or catheters has changed the job of school nurses.

Health Matters Allergies, other irritants cause adults to gasp for air (The Naperville Sun) - 203 weeks ago

Aaacchooo! The fall season has arrived in the Midwest. With all the beauty, many of us are reaching for tissues and allergy medicine while many others are painfully reminded that asthma is easily triggered this time of year.

Aid helps feed region's flood victims (Press & Sun-Bulletin) - 203 weeks ago

GREAT BEND, PA. -- Gloria Hauer lost her doublewide home in the June flooding -- but that's not all. "My wheelchair, my cane, my walker, my nebulizer, the bone stimulator for my leg --" continued Hauer, of Hallstead, Pa. "I lost 30 years of everything."

FDA approves Sepracor respiratory drug (The MetroWest Daily News) - 203 weeks ago

MARLBOROUGH -- Federal regulators have given the green light to a new respiratory drug developed by Sepracor Inc.

Sepracor says FDA OKs Brovana for lung disease (Reuters via Yahoo! News) - 204 weeks ago

Sepracor Inc. said on Friday that the U.S. Food and Drug Administration has approved its inhaled drug Brovana as a long-term, twice-daily maintenance treatment for patients with chronic obstructive pulmonary disease, including bronchitis and emphysema.

FDA Approves Sepracor's BROVANA(TM) (Arformoterol Tartrate) Inhalation Solution for Chronic Obstructive Pulmonary (FinanzNachrichten) - 204 weeks ago

Sepracor Inc. ( Nachrichten / Aktienkurs ) (Nasdaq: SEPR) today announced that the U.S. Food and Drug Administration (FDA) approved its New Drug Application (NDA) for BROVANA â„¢ (arformoterol tartrate) Inhalation Solution 15 mcg (micrograms) as a long-term, twice-daily (morning and evening), maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease

FDA Approves Sepracor's BROVANA(TM) (Arformoterol Tartrate) Inhalation Solution for Chronic Obstructive Pulmonary (Business Wire via Yahoo! Finance) - 204 weeks ago

MARLBOROUGH, Mass.----Sepracor Inc. today announced that the U.S. Food and Drug Administration approved its New Drug Application for BROVANA Inhalation Solution 15 mcg as a long-term, twice-daily , maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease , including chronic bronchitis and emphysema.

Trial begins in infant's death (Sun-Sentinel) - 204 weeks ago

All it would have taken to save infant Marissa Cadet's life was a 911 call, prosecutor Elizabeth Parker told a jury Wednesday.